TriangleTagraxofusp (NCT05442216)
Tagraxofusp trial for Acute Myeloid Leukemia (NCT05442216). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with newly diagnosed CD123-positive acute myeloid leukemia after a prior myeloid disorder treated with at least two hypomethylating-agent cycles. Patients must be unsuitable for, or decline, intensive chemotherapy.
The idea: tagraxofusp delivers a protein-production-blocking toxin through the interleukin-3 receptor. Azacitidine alters DNA methylation; venetoclax blocks BCL2 survival signaling. The three drugs are given in twenty-eight-day cycles. Marrow biopsies guide treatment; researchers measure complete remission and safety.
This phase 2 study plans 53 patients. Joshua Zeidner leads at the University of North Carolina, Chapel Hill; seven US sites recruit.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.